RWE Program Offers Sponsors Chance At Novel Uses, But In Exchange For Disclosing Proposals
Executive Summary
The disclosure requirement to participate includes an option for the US FDA to include the ideas on new regulatory uses for real-world evidence in a guidance or speak about them at public forums in order to ‘promote innovation.’
You may also be interested in...
US FDA ‘Advancing Real-World Evidence Program’ Has First Entrants
Agency is painting the new advice program as an attractive, ‘all-hands-on-deck’ option for sponsors beginning an RWE program for a new indication or a post-marketing commitment. With the first two slots filled, the next opportunity for sponsors has an end-of-September deadline.
Collaboration Makes The (Real) World Go Round: Global Efforts Strive To Anchor RWE With Real-World Data Standards And Practices
Can the decentralized global healthcare ecosystem to turn real-world evidence from a buzzword to a useful approach to fit-for-purpose evidence generation?
US FDA’s Pazdur Suggests NCI Should Help Sponsors Enroll Clinical Trials For Innovative Drugs
Oncology sponsors would handle ex-US trial enrollment, but Pazdur feels tapping into the NCI network would improve trial speed and diversity. Biggest challenge will likely be generating sponsor enthusiasm for move that would involve giving up some control of development.